Lawful Hemp Protection Act
- Sponsor
- Rep. Barr, Andy [R-KY-6]
- Committees
- Transportation and Infrastructure Committee (primary)
- Last action
- Jul 22, 2026
Bottom line
The "Lawful Hemp Protection Act" aims to federalize and standardize the regulation, taxation, and distribution of hemp-derived cannabinoid products, while cracking down on intoxicating synthetics and ensuring consumer safety.
What it actually does
This bill significantly redefines "hemp" under federal law, increasing the total THC limit to 1% but explicitly excluding synthetically derived cannabinoids and certain intermediate products. It grants the FDA comprehensive authority over hemp-derived cannabinoid products, mandating strict labeling, manufacturing, and testing requirements, and establishing maximum cannabinoid content. Furthermore, it imposes a new federal excise tax regime on these products, creates a three-tiered distribution system for hemp-derived beverages, and establishes a federal trust fund for oversight. It also links federal highway funds to state-level impaired driving laws for hemp and allows Medicare Advantage plans to cover hemp-derived cannabinoid products.
Proponents argue
Proponents argue that the bill creates a much-needed federal regulatory framework for the rapidly growing hemp-derived cannabinoid market, which currently operates in a legal gray area. They contend it protects consumers from potentially harmful synthetic intoxicants, ensures product safety and accurate labeling, and establishes a level playing field for legitimate hemp businesses. The age restrictions and impaired driving provisions are highlighted as crucial for public health and safety.
Opponents contend
Opponents might argue that the bill's new definitions and regulatory burdens, particularly the increased total THC limit combined with the exclusion of many popular cannabinoids, could stifle innovation and disproportionately harm small businesses in the existing hemp industry. The new federal taxes and the three-tiered distribution system for beverages could be seen as overregulation, increasing costs for consumers and creating barriers to market entry. Some may also criticize the federal overreach into state-level impaired driving laws.
The bill is moderately long and introduces complex regulatory and tax changes across multiple federal agencies, requiring significant time for a thorough review beyond a quick glance.
Section 3 of the bill, amending Section 297A of the Agricultural Marketing Act of 1946.
Redefinition of "Hemp" and Exclusion of Synthetic Cannabinoids
This section redefines "hemp" to mean Cannabis sativa L. with a total tetrahydrocannabinol (THC) concentration of not more than 1% on a dry weight basis (up from the current 0.3%). Crucially, it explicitly excludes any cannabinoids not naturally produced by the plant, or those produced using chemical synthesis, hydrogenation, acetylation, or other artificial processes that alter molecular structure (e.g., HHC, THC-O-acetate, THCP). It also defines "industrial hemp" and "unfinished hemp-cannabinoid ingredient."
Supporters argue
Supporters argue this redefinition is essential to close loopholes exploited by manufacturers of intoxicating synthetic cannabinoids, which pose public health risks and undermine the intent of the original hemp legalization. The 1% total THC limit provides more flexibility for farmers while still distinguishing hemp from illicit cannabis.
Critics contend
Critics might contend that the exclusion of certain cannabinoids, even if chemically modified, could eliminate a significant portion of the current hemp-derived product market, harming businesses that have invested in these products. They may also argue the 1% THC limit is still too restrictive for some cultivators.
Tradeoffs
Balances supporting the hemp industry with protecting consumers from potentially dangerous, unregulated synthetic intoxicants. It also navigates the tension between agricultural flexibility (1% THC) and strict product control (synthetic exclusions).
Section 4 of the bill, amending the Federal Food, Drug, and Cosmetic Act.
Establishment of FDA Regulatory Authority over Hemp-Derived Cannabinoid Products
This section brings "hemp-derived cannabinoid products" under FDA oversight, deeming them "food" for regulatory purposes. It prohibits their sale to individuals under 21, requires domestic sourcing and processing, and establishes strict adulteration and misbranding standards. These standards include maximum cannabinoid content (to be set by FDA, with default limits if FDA delays), exclusion of non-naturally occurring cannabinoids, and prohibitions on certain additives (alcohol, caffeine, melatonin). Labeling requirements are extensive, including THC content, warning statements, QR codes for testing results, and prohibitions on child-appealing packaging.
Section 5 of the bill, amending the Social Security Act.
Inclusion of Hemp-Derived Cannabinoid Products in Medicare Advantage and Beneficiary Incentives
This section allows Medicare Advantage (MA) plans to include coverage for hemp-derived cannabinoid products as a special supplemental benefit for the chronically ill, starting in the first plan year after enactment. It also establishes a "Substance Access Beneficiary Engagement Incentive" under certain CMI models, allowing providers to offer consultations and provision of hemp-derived cannabinoid products to applicable individuals.
Section 6 of the bill, adding a new Chapter 56 to Subtitle E of the Internal Revenue Code of 1986.
Federal Excise Taxes and Three-Tiered Distribution System
This section establishes a new federal tax regime for hemp-derived cannabinoid products. Hemp-derived beverages are taxed at 5 cents per milligram of THC. Other hemp-derived cannabinoid products are taxed at 5% of their sales price. Additionally, manufacturers of these products face a 5% tax on their annual sales revenue. It mandates a permit system for manufacturers and wholesalers and establishes a strict three-tiered distribution system (manufacturer -> wholesaler -> retailer) for hemp-derived beverages, prohibiting any person from holding interests in more than one tier. It also creates a Trust Fund for Oversight and allocates 1% of hemp beverage taxes to the Highway Trust Fund for impaired driving enforcement.
Section 7 of the bill.
Prohibition of Anti-Competitive Practices in Hemp-Derived Beverage Distribution
This section prohibits manufacturers and wholesalers of hemp-derived beverages from engaging in various anti-competitive practices. These include requiring retailers to exclusively purchase from them, inducing exclusive purchases through financial incentives or property interests, commercial bribery, and selling on consignment or conditional sale. Violations are misdemeanors subject to fines and product forfeiture.
Section 8 of the bill.
Restriction on Distribution of Unfinished Hemp-Cannabinoid Ingredients
This section makes it unlawful to market, sell, distribute, or ship "unfinished hemp-cannabinoid ingredients" to anyone other than a permitted manufacturer of hemp-derived cannabinoid products for further processing. Violations are misdemeanors, potentially leading to fines and permit suspension/revocation.
Section 9 of the bill, adding a new Section 180 to Chapter 1 of Title 23, United States Code.
Federal Mandate for State Impaired Driving Laws Related to Hemp
This section mandates that states adopt laws for impaired driving due to hemp that use the same field sobriety evaluation standards as for lawfully prescribed pharmaceutical substances. States must apply penalties for hemp impairment no less stringent than those for alcohol-related impairment. Failure to comply will result in a 10% withholding of federal highway funds (Section 104(b)(1) and (2)). It explicitly states it does not require a per se blood concentration threshold for hemp-derived cannabinoids.
Section 10 of the bill.
Preservation of State Rights and Non-Interference with Interstate Commerce
This section clarifies that the Act does not preempt or limit state, territory, or Indian Tribe authority to enact more stringent (or equally protective) laws governing hemp and hemp-derived cannabinoid products, comparable to an alcoholic beverage regulatory scheme. However, it explicitly prohibits states from enacting laws that prevent the passage and delivery of compliant hemp-derived cannabinoid products through their borders, citing the Interstate Commerce Clause.
The bill raises the total THC limit for "hemp" from 0.3% to 1% on a dry weight basis, which could be seen as a liberalization. However, immediately following this, it explicitly excludes "any intermediate hemp-derived cannabinoid product" or "final hemp-derived cannabinoid products" containing cannabinoids not naturally produced by Cannabis sativa L., or those produced via chemical synthesis, hydrogenation, acetylation, alkylation, or other artificial processes that alter molecular structure (e.g., HHC, THC-O-acetate, THCP).
Section 3(a)(2), amending Section 297A(1)(A) and (C) of the Agricultural Marketing Act of 1946.
Why it matters:This is likely a deliberate legislative strategy to appear to offer a benefit (higher THC limit) while simultaneously implementing a significant crackdown on products deemed problematic. The detailed chemical exclusions are necessary for legal precision but make the provision dense.
Case for: Proponents argue the 1% limit provides farmers with more cultivation flexibility, reducing the risk of "hot hemp" while the synthetic exclusions are critical for public safety and preventing the proliferation of intoxicating, unregulated substances.
Case against: Critics might contend that the 1% THC increase is a red herring if the subsequent exclusions effectively eliminate a large segment of the market, particularly for products like Delta-8 THC which, while naturally occurring, are often concentrated or converted through processes that might fall under the "artificial process" exclusion.
Estimated impact: Significant restructuring of the legal hemp market, potentially eliminating many existing products and business models, while offering a slight cultivation benefit.
If the Secretary of Health and Human Services (via FDA) fails to establish maximum allowable cannabinoid content amounts within 12 months of enactment, the bill sets default limits: 5 milligrams total THC per serving for oral consumption, 50 milligrams per serving for inhalable products, and 50 milligrams per serving for topical products.
Section 4(b)(4), adding Section 425(b)(4) to the Federal Food, Drug, and Cosmetic Act.
Why it matters:This serves as a legislative backstop, ensuring that some form of milligram limits are in place even if the FDA is slow to act. It provides a degree of certainty for the industry and consumers in the interim.
Case for: Proponents argue this prevents a regulatory vacuum and ensures that consumer safety is addressed promptly, even if the FDA faces delays in its rulemaking process.
Case against: Critics might argue that these default limits are arbitrary and may not be scientifically optimized for safety or efficacy, potentially being too restrictive or too lenient depending on the product type.
Estimated impact: Provides temporary, but significant, product formulation constraints for manufacturers if FDA delays.
The bill mandates the Secretary of the Treasury to establish and implement a three-tiered distribution system for hemp-derived beverages, mirroring the alcohol industry. This system strictly separates manufacturers, wholesalers, and retailers, prohibiting any person from holding interests in more than one tier.
Section 6(a), adding Subchapter D (Sec. 5904) to the new Chapter 56 of the Internal Revenue Code of 1986.
Why it matters:This is a significant structural change for the hemp beverage market, imposing a traditional, highly regulated model. It's placed within the tax chapter because the IRS (Treasury) traditionally oversees such systems for alcohol and tobacco.
Case for: Proponents argue this system promotes responsible distribution, enhances tax collection, and provides a clear chain of custody, reducing illicit sales and ensuring age verification, drawing parallels to the successful regulation of alcohol.
Case against: Critics contend that imposing such a rigid, capital-intensive system on a nascent industry could create immense barriers to entry for small businesses, stifle innovation, and lead to market consolidation. It might not be suitable for all types of hemp-derived beverages.
Estimated impact: Fundamental restructuring of the hemp-derived beverage market, potentially leading to significant consolidation and increased costs.